Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 160

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma

Open access
Habra, Mouhammed Amir, Stephen, Bettzy, Campbell, Matthew, Hess, Kenneth, Tapia, Coya, Xu, Mingxuan, Rodon Ahnert, Jordi, Jimenez, Camilo, Lee, Jeffrey E., Perrier, Nancy D., Boraddus, Russell R., Pant, Shubham, Subbiah, Vivek, Hong, David S., Zarifa, Abdulrazzak, Fu, Siqing, Karp, Daniel D., Meric-Bernstam, Funda, Naing, Aung · 2019 · Journal for ImmunoTherapy of Cancer

Abstract

BACKGROUND: Adrenocortical carcinoma (ACC) is a rare malignancy without good treatment options. There are limited data about the use of immunotherapy in ACC. We investigated the efficacy and safety of pembrolizumab in patients with metastatic ACC. METHODS: This is a pre-specified cohort of a single-center, investigator-initiated, phase II clinical trial using pembrolizumab monotherapy in patients with rare malignancies. Patients must have had prior treatment fail in the past 6 months before study enrollment. Patients were enrolled from August 2016 to October 2018. Follow-up data were updated as of March 26, 2019. Patients received 200 mg pembrolizumab intravenously every 3 weeks without concomitant oncologic therapy. The primary endpoint was non-progression rate (NPR) at 27 weeks. Other endpoints included adverse events, tumor responses measured independently by objective radiologic criteria, and select immunological markers. RESULTS: Sixteen patients with ACC (including eight women [50%]) were included in this cohort. Ten patients (63%) had evidence of hormonal overproduction (seven had cortisol-producing ACC). Non-progression rate at 27 weeks was evaluable in 14 patients, one patient was lost to follow-up, and one patient left the study because of an adverse event. Five of 14 patients were alive and progression-free at 27 weeks (non-progression rate at 27 weeks was 36, 95% confidence interval 13-65%). Of the 14 patients evaluable for imaging response by immune-related Response Evaluation Criteria in Solid Tumors, two had a partial response (including one with cortisol-producing ACC), seven had stable disease (including three with cortisol-producing ACC), and five had progressive disease, representing an objective response rate of 14% (95% confidence interval 2-43%). Of those who had stable disease, six had disease stabilization that lasted ≥4 months. Severe treatment-related adverse events (≥grade 3) were seen in 2 of 16 patients (13%) and resulted in one patient discontinuing study participation. All studied tumor specimens (14/14) were negative for programmed cell death ligand-1 expression. Thirteen of 14 tumor specimens (93%) were microsatellite-stable. Eight of 14 patients (57%) had a high tumor-infiltrating lymphocyte score on immunohistochemistry staining. CONCLUSIONS: Single-agent pembrolizumab has modest efficacy as a salvage therapy in ACC regardless of the tumor's hormonal function, microsatellite instability status, or programmed cell death ligand-1 status. Treatment was well tolerated in most study participants, with a low rate of severe adverse events. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02721732 , Registered March 29, 2016.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-019-0722-x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 160

Metadata

Authors
Habra, M. A., Stephen, B., Campbell, M., Hess, K., Tapia, C., Xu, M., Rodon Ahnert, J., Jimenez, C., Lee, J. E., Perrier, N. D., Boraddus, R. R., Pant, S., Subbiah, V., Hong, D. S., Zarifa, A., Fu, S., Karp, D. D., Meric-Bernstam, F., & Naing, A.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2019-09-18
Volume
7
Issue
1
Pages
253-253
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2974072238
Cited by
160
References
4
FWCI
16.20
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. https://app.cochat.ai/papers/10.1186/s40425-019-0722-x
The paper
Habra, M. A., Stephen, B., Campbell, M., Hess, K., Tapia, C., Xu, M., Rodon Ahnert, J., Jimenez, C., Lee, J. E., Perrier, N. D., Boraddus, R. R., Pant, S., Subbiah, V., Hong, D. S., Zarifa, A., Fu, S., Karp, D. D., Meric-Bernstam, F., & Naing, A. (2019). Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-019-0722-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.